Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600645's EV-to-FCF is ranked worse than 63.58% of 335
companies
in the Biotechnology industry
Industry Median: 15.51
vs SHSE:600645: 26.82
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhongyuan Union Cell & Gene Engineering's PE Ratio (TTM) for today is calculated as:
Zhongyuan Union Cell & Gene Engineering's share price for today is ¥17.85.
Zhongyuan Union Cell & Gene Engineering's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhongyuan Union Cell & Gene Engineering EV-to-FCF Related Terms
Zhongyuan Union Cell & Gene Engineering EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering EV-to-FCF Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering EV-to-FCF vs Biotechnology Industry
Zhongyuan Union Cell & Gene Engineering's current Enterprise Value is ¥7,325 Mil.
Zhongyuan Union Cell & Gene Engineering's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥249 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a EV-to-FCF of 29.47 as of Jul. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. This is 31% below median its historical median of 42.89. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #213 out of 335 companies in the Biotechnology industry, placing it in the top 63.6%.
Is Zhongyuan Union Cell & Gene Engineering's EV-to-FCF too high?
Zhongyuan Union Cell & Gene Engineering's current EV-to-FCF of 29.47 is 31% below median its 10-year median of 42.89. The Biotechnology industry median EV-to-FCF is 15.51. Zhongyuan Union Cell & Gene Engineering's value of 29.47 is 90% above this industry median. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #213 out of 335 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #213 out of 335 companies for EV-to-FCF. This places Zhongyuan Union Cell & Gene Engineering in the lower half of its industry. The industry median EV-to-FCF is 15.51. Zhongyuan Union Cell & Gene Engineering's value of 29.47 is 90% above this benchmark. While the company's 10-year median is 42.89 vs. the industry median of 15.51, Zhongyuan Union Cell & Gene Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.51, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongyuan Union Cell & Gene Engineering's current EV-to-FCF of 29.47 is 90% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current EV-to-FCF is 29.47, which is 31% below median its own 10-year median of 42.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.38, compared to a current price of ¥17.85 — trading 12.4% below its estimated fair value. The current EV-to-FCF is 29.47, which is 31% below median its 10-year median of 42.89 and 90% above the Biotechnology industry median of 15.51. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current EV-to-FCF is 29.47 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥17.85 is trading 12.4% below its estimated GF Value™ of ¥20.38.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
EV-to-FCF: 29.47 (31% below median its 10-year median of 42.89)
GF Value™: ¥20.38 vs. price of ¥17.85 (12.4% below fair value)
Industry Position: 90% above the Biotechnology median (#213 of 335)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Business Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
60GF Score
Get the complete analysis for SHSE:600645
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
